Abstract:Background: Heart failure occurs in ~10% of patients with acute rheumatic fever (RF), and several studies have shown that cardiac decompensation in RF results primarily from valvular disease and is not due to primary myocarditis. However, the literature on this topic is scarce, and a recent case series has shown that recurrent RF can cause ventricular dysfunction even in the absence of valvular heart disease.Methods: The present study evaluated the clinical, laboratory and imaging characteristics of 25 consecu… Show more
“…Rheumatic heart disease, a systemic immune process provoked by a beta-hemolytic streptococcal infection, represents the most frequently acquired heart disease in developing countries [44]; despite it classically involving valves, and it has been reported that at least 10% of patients develop a secondary HF due to valve involvement, recent evidence showed that 25-30% of subjects undergoing heart transplantation had non-diagnosed myocarditis, leading to refractory heart failure and, ultimately, heart transplantation [45].…”
Section: Specific Forms Of Myocarditismentioning
confidence: 99%
“…Recently, it has been shown that about 70% of patients with rheumatic heart disease display a positive 18F-FDG PET/CT and that 90% of patients have a positive uptake of t-gallium-67 cardiac scintigraphy, regardless of LVEF [44].…”
Myocarditis is a disease caused by cardiac inflammation that can progress to dilated cardiomyopathy, heart failure, and eventually death. Several etiologies, including autoimmune, drug-induced, and infectious, lead to inflammation, which causes damage to the myocardium, followed by remodeling and fibrosis. Although there has been an increasing understanding of pathophysiology, early and accurate diagnosis, and effective treatment remain challenging due to the high heterogeneity. As a result, many patients have poor prognosis, with those surviving at risk of long-term sequelae. Current diagnostic methods, including imaging and endomyocardial biopsy, are, at times, expensive, invasive, and not always performed early enough to affect disease progression. Therefore, the identification of accurate, cost-effective, and prognostically informative biomarkers is critical for screening and treatment. The review then focuses on the biomarkers currently associated with these conditions, which have been extensively studied via blood tests and imaging techniques. The information within this review was retrieved through extensive literature research conducted on major publicly accessible databases and has been collated and revised by an international panel of experts. The biomarkers discussed in the article have shown great promise in clinical research studies and provide clinicians with essential tools for early diagnosis and improved outcomes.
“…Rheumatic heart disease, a systemic immune process provoked by a beta-hemolytic streptococcal infection, represents the most frequently acquired heart disease in developing countries [44]; despite it classically involving valves, and it has been reported that at least 10% of patients develop a secondary HF due to valve involvement, recent evidence showed that 25-30% of subjects undergoing heart transplantation had non-diagnosed myocarditis, leading to refractory heart failure and, ultimately, heart transplantation [45].…”
Section: Specific Forms Of Myocarditismentioning
confidence: 99%
“…Recently, it has been shown that about 70% of patients with rheumatic heart disease display a positive 18F-FDG PET/CT and that 90% of patients have a positive uptake of t-gallium-67 cardiac scintigraphy, regardless of LVEF [44].…”
Myocarditis is a disease caused by cardiac inflammation that can progress to dilated cardiomyopathy, heart failure, and eventually death. Several etiologies, including autoimmune, drug-induced, and infectious, lead to inflammation, which causes damage to the myocardium, followed by remodeling and fibrosis. Although there has been an increasing understanding of pathophysiology, early and accurate diagnosis, and effective treatment remain challenging due to the high heterogeneity. As a result, many patients have poor prognosis, with those surviving at risk of long-term sequelae. Current diagnostic methods, including imaging and endomyocardial biopsy, are, at times, expensive, invasive, and not always performed early enough to affect disease progression. Therefore, the identification of accurate, cost-effective, and prognostically informative biomarkers is critical for screening and treatment. The review then focuses on the biomarkers currently associated with these conditions, which have been extensively studied via blood tests and imaging techniques. The information within this review was retrieved through extensive literature research conducted on major publicly accessible databases and has been collated and revised by an international panel of experts. The biomarkers discussed in the article have shown great promise in clinical research studies and provide clinicians with essential tools for early diagnosis and improved outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.